Proceedings from a CME webinar focused on COVID-19 and chronic
lymphocytic leukemia. Featuring perspectives from Drs Matthew S
Davids, Anthony R Mato and Jeff Sharman.
Changes in chronic lymphocytic leukemia (CLL) institutional
processes and procedures brought on by the COVID-19 pandemic
(00:00)
Case: A woman in her late 50s with a history
of breast cancer requires treatment for CLL during the pandemic
(9:03)
Recommendations regarding the management of CLL in the COVID-19
environment (14:37)
Rationale for the use of Bruton tyrosine kinase inhibitors for
patients with cancer and COVID-19 (18:29)
Current approach for patients with CLL requiring treatment with
venetoclax/obinutuzumab (20:49)
Case: A woman in her early 60s with CLL in
remission after treatment with an obinutuzumab-based therapy on a
clinical trial receives results of a prescribed study-related CT
scan that are suspicious for COVID-19 infection (28:16)
Limitations of COVID-19 testing techniques and platforms
(drive-through testing, false-negative rates, et cetera)
(34:31)
Case: A man in his early 70s with
relapsed/refractory CLL is hospitalized with COVID-19; potential
role of noncancer therapeutic interventions (eg, remdesivir,
anticoagulants) (39:44)
Perspectives on continuing versus stopping therapy both before
and during the current pandemic (47:18)
Case: A man in his early 70s who is receiving
PI3 kinase inhibitor therapy for relapsed/refractory CLL begins to
experience symptoms of COVID-19 after his wife tests positive for
the novel coronavirus (53:03)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.